

Noida, Uttar Pradesh, India

Thursday, April 16, 2020

Press Statement

Jubilant Life Sciences Limited noted in a press statement today that no traces of COVID-19 virus have been found in the imported Raw Material sampled from Nanjangud facility of its subsidiary - Jubilant Generics Limited. Raw Material (imported from China) tested negative for COVID-19 virus by National Institute of Virology, Pune as announced by the authorities of Government of Karnataka.

It is unfortunate that a wrong perception was created in public and media about the Raw Material imported from China.

Additionally, the Company clarified that Patient P52 did not travel to China or on any overseas trip in the last six months. Further, none of the employees tested positive so far travelled overseas in the last six months.

Jubilant Generics Limited at its plant located at Nanjangud, Mysore manufactures Active Pharmaceutical Ingredients used in drugs that are needed for sustaining patients' lives, including Azithromycin Dihydrate and Azithromycin Monohydrate, which are needed to fight the global menace of COVID-19.

All evidences and known scientific facts published by reputed global organisations, available so far, indicates that the virus does not survive for more than 72hours on any surface. The Raw Materials sampled from the Nanjangud facility had taken more than three weeks (>21days) of transit to reach the plant by Sea Route and no virus can survive this long on any surface.

In any case, Patient P52, the first positive case of COVID-19 from the Nanjangud facility, never had any contact with any raw material nor had role in Receiving, Transporting, Handling or Storage of raw materials.

Jubilant values the health and safety of employees and community in and around its facility. It is continuously working towards ensuring that all their needs are met and necessary precautionary measures as directed by Government protocols are being followed.



The Company values the support it has received from all levels of Government authorities including District administration, Police, Public health department and the community around its facility. Jubilant is constantly communicating and working with them to mitigate the situation arising of the COVID-19.

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery & Development Solutions businesses. Pharmaceuticals business, through Jubilant Pharma Limited, Singapore (JPL), is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectables & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through five manufacturing facilities in India. Drug Discovery & Development Solutions comprises Drug Discovery Services (DDS) business through Jubilant Biosys Limited & Jubilant Chemsys Limited and Proprietary Drug Discovery business through Jubilant Therapeutics. DDS provides innovation and collaborative research through two world class research centers in Bangalore and Noida in India and Jubilant Therapeutics is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Life Sciences Limited has a team of around 8,000 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info, please visit www.jubl.com.



For more information, please contact:

For Investors

Vineet Mayer
Jubilant Life Sciences Limited
E-mail: vineet.mayer@jubl.com

Siddharth Rangnekar
CDR India
E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya
Jubilant Life Sciences Limited
E-mail: sudhakar.safaya@jubl.com

Desiree Crasto
Madison Public Relations
E-mail: desiree.crasto@madisonpr.in
Phone number: +91 9819541498

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

